search
Include:
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
6,722 Research products, page 1 of 673

  • Canada
  • Publications
  • Research data
  • GR

10
arrow_drop_down
Relevance
arrow_drop_down
  • Open Access
    Authors: 
    Montserrat Garcia-Closas; Fergus J. Couch; Kyriaki Michailidou; Marjanka K. Schmidt; Mark N. Brook; Nick Orr; Suhn K. Rhie; Elio Riboli; Heather Spencer Feigelson; Loic Le Marchand; +207 more
    Publisher: Springer Nature
    Countries: Netherlands, Ireland, United Kingdom, United Kingdom
    Project: CIHR , NIH | Characterizing Genetic Su... (5U01CA098233-06), NIH | Discovery Expansion and R... (5U19CA148065-04), NIH | Breast &prostate cancer &... (1U01CA098216-01), NIH | Breast &Prostate Cancer &... (1U01CA098758-01), WT , EC | COGS (223175), NIH | Characterizing Genetic Su... (5U01CA098710-06), NIH | Genetic epidemiology of c... (3R01CA122340-03S1)

    Estrogen receptor (ER)-negative tumors represent 20-30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition. To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environment Study (COGS). SNPs at four loci, 1q32.1 (MDM4, P= 2.1 x 10(-12) and LGR6, P = 1.4 x 10(-8)), 2p24.1 (P = 4.6 x 10(-8)) and 16q12.2 (FTO, P = 4.0 x 10(-8)), were associated with ER-negative but not ER-positive breast cancer (P> 0.05). These findings provide further evidence for distinct etiological pathways associated with invasive ER-positive and ER-negative breast cancers.

  • Open Access
    Authors: 
    T. Aaltonen; Ronen Alon; S. Amerio; A. Anastassov; Alberto Annovi; Giorgio Apollinari; J. A. Appel; J. Asaadi; W. Ashmanskas; A. Aurisano; +207 more
    Publisher: arXiv
    Countries: Spain, Italy
    Project: EC | TAUKITFORNEWPHYSICS (302103), SNSF | Measurements of Higgs bos... (153664), NSERC

    This work was supported by the U.S. Department of Energy and National Science Foundation; the Italian Istituto Nazionale di Fisica Nucleare; the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Natural Sciences and Engineering Research Council of Canada; the National Science Council of the Republic of China; the Swiss National Science Foundation; the A. P. Sloan Foundation; the Bundesministerium für Bildung und Forschung, Germany; the Korean World Class University Program, the National Research Foundation of Korea; the Science and Technology Facilities Council and the Royal Society, United Kingdom; the Russian Foundation for Basic Research; the Ministerio de Ciencia e Innovación, and Programa Consolider-Ingenio 2010, Spain; the Slovak R&D Agency; the Academy of Finland; the Australian Research Council (ARC); and the EU community Marie Curie Fellowship Contract No. 302103. This work was also supported by the Shrum Foundation, the Weizman Institute of Science and the Israel Science Foundation. Results of a study of the substructure of the highest transverse momentum (pT) jets observed by the CDF Collaboration are presented. Events containing at least one jet with pT>400 GeV/c in a sample corresponding to an integrated luminosity of 5.95 fb−1, collected in 1.96 TeV proton-antiproton collisions at the Fermilab Tevatron collider, are selected. A study of the jet mass, angularity, and planar-flow distributions is presented, and the measurements are compared with predictions of perturbative quantum chromodynamics. A search for boosted top-quark production is also described, leading to a 95% confidence level upper limit of 38 fb on the production cross section of top quarks with pT>400 GeV/c. Peer Reviewed et al.

  • Open Access
    Authors: 
    George Bazoukis; Emmanouil S. Brilakis; Gary Tse; Konstantinos P. Letsas; Panagiotis Kitsoulis; Tong Liu; Adrian Baranchuk; Antonios Sideris; Costas Tsioufis; Stavros Stavrakis;
    Publisher: Wiley

    Objectives The aim of our systematic review was to investigate the efficacy of coronary sinus (CS) reducer device in patients with refractory angina. Background The CS reducer device provides a therapeutic option for patients with coronary artery disease who are not suitable for revascularization. Methods Two independent investigators (GB and GT) systematically searched the Medline and Cochrane library databases for studies describing the efficacy and safety of the CS reducer in patients with refractory angina from January 1, 2000 until May 12, 2018 using the following terms: "coronary sinus (reducer OR reducing) device." Efficacy was defined as ≥1 unit improvement in the Canadian cardiovascular society (CCS) score. Results Our search strategy provided six studies (five observational studies and one randomized clinical trial) with 196 patients. The CS reducer device was effective in 146/186 (78.5%) patients. CCS score improved from 3.2 at baseline to 1.9 after 8.6 months of follow-up. The efficacy of CS reducer device was also demonstrated as an improvement in Seattle Angina Questionnaire score, dobutamine echocardiography, thalium single-photon emission computed tomography perfusion studies, 6-min-walk test and myocardial perfusion reserve index. Implantation failed in 4 of 196 (2%) patients and 5 patients (2.5%) had a complication during 30-day follow-up. Conclusions The CS reducer is a promising treatment option for patients with refractory angina who are not candidates for revascularization. However, larger randomized control trials with long-term follow-up are needed to elucidate its role.

  • Open Access English
    Authors: 
    Anne Lise Courbis; Ruth Murray; Sylvie Arnavielhe; Davide Caimmi; Anna Bedbrook; Michiel van Eerd; Govert De Vries; Gérard Dray; Ioana Agache; Mário Morais-Almeida; +32 more
    Publisher: HAL CCSD
    Countries: Finland, Turkey, France, Greece

    Background: Allergic rhinitis (AR) management has changed in recent years following the switch from the concept of disease severity to the concept of disease control, publication of the AR clinical decision support system (CDSS) and development of mobile health (m-health) tools for patients (eg Allergy Diary). The Allergy Diary Companion app for healthcare providers is currently being developed and will be launched in 2018. It incorporates the AR CDSS to provide evidence-based treatment recommendations, linking all key stakeholders in AR management. Objective: To produce an electronic version of the AR CDSS (e-CDSS) for incorporation into the Allergy Diary Companion, to describe the app interfaces used to collect information necessary to inform the e-CDSS and to summarize some key features of the Allergy Diary Companion. Methods: The steps involved in producing the e-CDSS and incorporating it into the Allergy Diary Companion were (a) generation of treatment management scenarios; (b) expert consensus on treatment recommendations; (c) generation of electronic decisional algorithms to describe all AR CDSS scenarios; (d) digitization of these algorithms to form the e-CDSS; and (e) embedding the e-CDSS into the app to permit easy user e-CDSS interfacing. Results: Key experts in the AR field agreed on the AR CDSS approach to AR management and on specific treatment recommendations provided by Allergy Diary Companion. Based on this consensus, decision processes were developed and programmed into the Allergy Diary Companion using Titanium Appcelerator (JavaScript) for IOS tablets. To our knowledge, this is the first time the development of any m-health tool has been described in this transparent and detailed way, providing confidence, not only in the app, but also in the provided management recommendations. Conclusion: The Allergy Diary Companion for providers provides guideline and expert-endorsed AR management recommendations. [MASK paper No 32]. © 2018 John Wiley & Sons Ltd

  • Closed Access
    Authors: 
    P. K. Shufflebotham; Howard C. Card; Adonios Thanailakis;
    Publisher: Wiley

    A review of amorphous silicon alloys (other than a-Si: H) is presented. The main focus is on experimental results. Methods of fabricating amorphous alloys are classified and their basic operational principles outlined. The electrical and optical properties of amorphous silicon based alloys are then described, and a summary of existing and potential applications given. Conspicuous gaps in the fabrication, understanding and application of these materials are pointed out. A comprehensive (though not exhaustive) bibliography is presented, with references to all amorphous silicon alloys studied up to the summer of 1986.

  • Open Access
    Authors: 
    Georges Aad; Leszek Adamczyk; Jahred Adelman; Tim Adye; Tatjana Agatonovic-Jovin; J. A. Aguilar-Saavedra; Faig Ahmadov; Giulio Aielli; Gian Luigi Alberghi; J. Albert; +599 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    Many extensions of the Standard Model posit the existence of heavy particles with long lifetimes. This article presents the results of a search for events containing at least one long-lived particle that decays at a significant distance from its production point into two leptons or into five or more charged particles. This analysis uses a data sample of proton-proton collisions at root s = 8 TeV corresponding to an integrated luminosity of 20.3 fb(-1) collected in 2012 by the ATLAS detector operating at the Large Hadron Collider. No events are observed in any of the signal regions, and limits are set on model parameters within supersymmetric scenarios involving R-parity violation, split supersymmetry, and gauge mediation. In some of the search channels, the trigger and search strategy are based only on the decay products of individual long-lived particles, irrespective of the rest of the event. In these cases, the provided limits can easily be reinterpreted in different scenarios.

  • Publication . Article . Other literature type . 2020
    Open Access English
    Authors: 
    Konark Malhotra; Nitin Goyal; Aristeidis H. Katsanos; Angeliki Filippatou; Eva Mistry; Pooja Khatri; Mohammad Anadani; Alejandro M Spiotta; Else Charlotte Sandset; Amrou Sarraj; +9 more

    Limited data exist evaluating the effect of blood pressure (BP) on clinical outcomes among patients with acute ischemic stroke with large vessel occlusion treated with mechanical thrombectomy (MT). We sought to evaluate the association of BP levels on clinical outcomes among patients with acute ischemic stroke with large vessel occlusion treated with MT. Studies were identified that reported the association of systolic BP (SBP) or diastolic BP levels before, during, or after MT on the outcomes of patients with acute ischemic stroke treated with MT. Unadjusted and adjusted analyses of studies reporting odds ratios (OR adj ) per 10 mm Hg BP increment were performed. Our analysis included 25 studies comprising 6474 patients. Higher pre-MT mean SBP ( P =0.008) and post-MT maximum SBP ( P =0.009) levels were observed in patients who died within 3 months. Patients with 3-month functional independence were noted to have lower pre-MT ( P <0.001) and post-MT maximum SBP levels ( P <0.001). In adjusted analyses, increasing post-MT maximum SBP and diastolic BP levels were associated with 3-month mortality (OR adj , 1.19 [95% CI,1.00–1.43]; I 2 =78%, P value for Cochran Q test: 0.001) and symptomatic intracranial hemorrhage (OR adj , 1.65 [95% CI, 1.11–2.44]; I 2 =0%, P value for Cochran Q test: 0.80), respectively. Increasing pre- and post-MT mean SBP levels were associated with lower odds of 3-month functional independence (OR adj , 0.86 [95% CI, 0.77–0.96]; I 2 =18%, P value for Cochran Q test: 0.30) and (OR adj , 0.80 [95% CI, 0.72–0.89]; I 2 =0%, P value for Cochran Q test: 0.51), respectively. In conclusion, elevated BP levels before and after MT are associated with adverse outcomes among patients with acute ischemic stroke with large vessel occlusion.

  • Publication . Article . Preprint . Other literature type . 2013
    Open Access
    Authors: 
    Cornelius A. Rietveld; Sarah E. Medland; Jaime Derringer; Jian Yang; Tõnu Esko; Nicolas W. Martin; Harm-Jan Westra; Konstantin Shakhbazov; Abdel Abdellaoui; Arpana Agrawal; +173 more
    Countries: United Kingdom, Croatia, Netherlands, Australia, United States
    Project: NIH | NBER Center for Aging and... (5P30AG012810-15), EC | DEVHEALTH (269874), NSF | EAGER Proposal: Workshop ... (1064089), WT , NIH | FINANCIAL STATUS--RETIREM... (2P01AG005842-04), NIH | ECONOMICS OF AGING TRAINI... (5T32AG000186-10), EC | GMI (230374)

    A genome-wide association study (GWAS) of educational attainment was conducted in a discovery sample of 101,069 individuals and a replication sample of 25,490. Three independent single-nucleotide polymorphisms (SNPs) are genome-wide significant (rs9320913, rs11584700, rs4851266), and all three replicate. Estimated effects sizes are small (coefficient of determination R2 ≈ 0.02%), approximately 1 month of schooling per allele. A linear polygenic score from all measured SNPs accounts for ≈2% of the variance in both educational attainment and cognitive function. Genes in the region of the loci have previously been associated with health, cognitive, and central nervous system phenotypes, and bioinformatics analyses suggest the involvement of the anterior caudate nucleus. These findings provide promising candidate SNPs for follow-up work, and our effect size estimates can anchor power analyses in social-science genetics. Economics

  • Open Access
    Authors: 
    Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Maximiliano Sioli; Nello Bruscino; Toshi Sumida; Andrei Snesarev; +834 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.

  • Open Access English
    Authors: 
    Fergus J. Couch; Kyriaki Michailidou; Gustavo Mendoza-Fandiño; Janna Lilyquist; Emily Hallberg; Simona Agata; Christine B. Ambrosone; Irene L. Andrulis; Hoda Anton-Culver; Volker Arndt; +194 more
    Publisher: Uppsala universitet, Institutionen för immunologi, genetik och patologi
    Countries: Norway, Spain, Finland, China (People's Republic of), United Kingdom, United States, United Kingdom, Denmark, Spain, United Kingdom ...
    Project: NWO | Secure and gentle grip of... (11477), WT , NIH | Discovery Expansion and R... (5U19CA148065-04), NIH | Follow-up of Ovarian Canc... (3U19CA148112-04S1), EC | COGS (223175), CIHR , NIH | A genome-wide association... (5R01CA128978-02), NIH | Elucidating Loci Involved... (5U19CA148537-02)

    Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ∼11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction. B.C.A.C. was funded through a European Community Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175; COGS); Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692); the National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), R01 grants (CA128978, CA176785, CA192393), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative); the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, the Breast Cancer Res. Foundation, and the Ovarian Cancer Research Fund. CIMBA genotyping was supported by National Institutes of Health grant (CA128978); the Department of Defence (W81XWH-10-1-0341); and the Breast Cancer Res. Foundation. CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. This is the final version of the article. It first appeared from Nature Publishing Group via http://dx.doi.org/10.1038/ncomms11375

search
Include:
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
6,722 Research products, page 1 of 673
  • Open Access
    Authors: 
    Montserrat Garcia-Closas; Fergus J. Couch; Kyriaki Michailidou; Marjanka K. Schmidt; Mark N. Brook; Nick Orr; Suhn K. Rhie; Elio Riboli; Heather Spencer Feigelson; Loic Le Marchand; +207 more
    Publisher: Springer Nature
    Countries: Netherlands, Ireland, United Kingdom, United Kingdom
    Project: CIHR , NIH | Characterizing Genetic Su... (5U01CA098233-06), NIH | Discovery Expansion and R... (5U19CA148065-04), NIH | Breast &prostate cancer &... (1U01CA098216-01), NIH | Breast &Prostate Cancer &... (1U01CA098758-01), WT , EC | COGS (223175), NIH | Characterizing Genetic Su... (5U01CA098710-06), NIH | Genetic epidemiology of c... (3R01CA122340-03S1)

    Estrogen receptor (ER)-negative tumors represent 20-30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition. To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environment Study (COGS). SNPs at four loci, 1q32.1 (MDM4, P= 2.1 x 10(-12) and LGR6, P = 1.4 x 10(-8)), 2p24.1 (P = 4.6 x 10(-8)) and 16q12.2 (FTO, P = 4.0 x 10(-8)), were associated with ER-negative but not ER-positive breast cancer (P&gt; 0.05). These findings provide further evidence for distinct etiological pathways associated with invasive ER-positive and ER-negative breast cancers.

  • Open Access
    Authors: 
    T. Aaltonen; Ronen Alon; S. Amerio; A. Anastassov; Alberto Annovi; Giorgio Apollinari; J. A. Appel; J. Asaadi; W. Ashmanskas; A. Aurisano; +207 more
    Publisher: arXiv
    Countries: Spain, Italy
    Project: EC | TAUKITFORNEWPHYSICS (302103), SNSF | Measurements of Higgs bos... (153664), NSERC

    This work was supported by the U.S. Department of Energy and National Science Foundation; the Italian Istituto Nazionale di Fisica Nucleare; the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Natural Sciences and Engineering Research Council of Canada; the National Science Council of the Republic of China; the Swiss National Science Foundation; the A. P. Sloan Foundation; the Bundesministerium für Bildung und Forschung, Germany; the Korean World Class University Program, the National Research Foundation of Korea; the Science and Technology Facilities Council and the Royal Society, United Kingdom; the Russian Foundation for Basic Research; the Ministerio de Ciencia e Innovación, and Programa Consolider-Ingenio 2010, Spain; the Slovak R&D Agency; the Academy of Finland; the Australian Research Council (ARC); and the EU community Marie Curie Fellowship Contract No. 302103. This work was also supported by the Shrum Foundation, the Weizman Institute of Science and the Israel Science Foundation. Results of a study of the substructure of the highest transverse momentum (pT) jets observed by the CDF Collaboration are presented. Events containing at least one jet with pT>400 GeV/c in a sample corresponding to an integrated luminosity of 5.95 fb−1, collected in 1.96 TeV proton-antiproton collisions at the Fermilab Tevatron collider, are selected. A study of the jet mass, angularity, and planar-flow distributions is presented, and the measurements are compared with predictions of perturbative quantum chromodynamics. A search for boosted top-quark production is also described, leading to a 95% confidence level upper limit of 38 fb on the production cross section of top quarks with pT>400 GeV/c. Peer Reviewed et al.

  • Open Access
    Authors: 
    George Bazoukis; Emmanouil S. Brilakis; Gary Tse; Konstantinos P. Letsas; Panagiotis Kitsoulis; Tong Liu; Adrian Baranchuk; Antonios Sideris; Costas Tsioufis; Stavros Stavrakis;
    Publisher: Wiley

    Objectives The aim of our systematic review was to investigate the efficacy of coronary sinus (CS) reducer device in patients with refractory angina. Background The CS reducer device provides a therapeutic option for patients with coronary artery disease who are not suitable for revascularization. Methods Two independent investigators (GB and GT) systematically searched the Medline and Cochrane library databases for studies describing the efficacy and safety of the CS reducer in patients with refractory angina from January 1, 2000 until May 12, 2018 using the following terms: "coronary sinus (reducer OR reducing) device." Efficacy was defined as ≥1 unit improvement in the Canadian cardiovascular society (CCS) score. Results Our search strategy provided six studies (five observational studies and one randomized clinical trial) with 196 patients. The CS reducer device was effective in 146/186 (78.5%) patients. CCS score improved from 3.2 at baseline to 1.9 after 8.6 months of follow-up. The efficacy of CS reducer device was also demonstrated as an improvement in Seattle Angina Questionnaire score, dobutamine echocardiography, thalium single-photon emission computed tomography perfusion studies, 6-min-walk test and myocardial perfusion reserve index. Implantation failed in 4 of 196 (2%) patients and 5 patients (2.5%) had a complication during 30-day follow-up. Conclusions The CS reducer is a promising treatment option for patients with refractory angina who are not candidates for revascularization. However, larger randomized control trials with long-term follow-up are needed to elucidate its role.

  • Open Access English
    Authors: 
    Anne Lise Courbis; Ruth Murray; Sylvie Arnavielhe; Davide Caimmi; Anna Bedbrook; Michiel van Eerd; Govert De Vries; Gérard Dray; Ioana Agache; Mário Morais-Almeida; +32 more
    Publisher: HAL CCSD
    Countries: Finland, Turkey, France, Greece

    Background: Allergic rhinitis (AR) management has changed in recent years following the switch from the concept of disease severity to the concept of disease control, publication of the AR clinical decision support system (CDSS) and development of mobile health (m-health) tools for patients (eg Allergy Diary). The Allergy Diary Companion app for healthcare providers is currently being developed and will be launched in 2018. It incorporates the AR CDSS to provide evidence-based treatment recommendations, linking all key stakeholders in AR management. Objective: To produce an electronic version of the AR CDSS (e-CDSS) for incorporation into the Allergy Diary Companion, to describe the app interfaces used to collect information necessary to inform the e-CDSS and to summarize some key features of the Allergy Diary Companion. Methods: The steps involved in producing the e-CDSS and incorporating it into the Allergy Diary Companion were (a) generation of treatment management scenarios; (b) expert consensus on treatment recommendations; (c) generation of electronic decisional algorithms to describe all AR CDSS scenarios; (d) digitization of these algorithms to form the e-CDSS; and (e) embedding the e-CDSS into the app to permit easy user e-CDSS interfacing. Results: Key experts in the AR field agreed on the AR CDSS approach to AR management and on specific treatment recommendations provided by Allergy Diary Companion. Based on this consensus, decision processes were developed and programmed into the Allergy Diary Companion using Titanium Appcelerator (JavaScript) for IOS tablets. To our knowledge, this is the first time the development of any m-health tool has been described in this transparent and detailed way, providing confidence, not only in the app, but also in the provided management recommendations. Conclusion: The Allergy Diary Companion for providers provides guideline and expert-endorsed AR management recommendations. [MASK paper No 32]. © 2018 John Wiley & Sons Ltd

  • Closed Access
    Authors: 
    P. K. Shufflebotham; Howard C. Card; Adonios Thanailakis;
    Publisher: Wiley

    A review of amorphous silicon alloys (other than a-Si: H) is presented. The main focus is on experimental results. Methods of fabricating amorphous alloys are classified and their basic operational principles outlined. The electrical and optical properties of amorphous silicon based alloys are then described, and a summary of existing and potential applications given. Conspicuous gaps in the fabrication, understanding and application of these materials are pointed out. A comprehensive (though not exhaustive) bibliography is presented, with references to all amorphous silicon alloys studied up to the summer of 1986.

  • Open Access
    Authors: 
    Georges Aad; Leszek Adamczyk; Jahred Adelman; Tim Adye; Tatjana Agatonovic-Jovin; J. A. Aguilar-Saavedra; Faig Ahmadov; Giulio Aielli; Gian Luigi Alberghi; J. Albert; +599 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    Many extensions of the Standard Model posit the existence of heavy particles with long lifetimes. This article presents the results of a search for events containing at least one long-lived particle that decays at a significant distance from its production point into two leptons or into five or more charged particles. This analysis uses a data sample of proton-proton collisions at root s = 8 TeV corresponding to an integrated luminosity of 20.3 fb(-1) collected in 2012 by the ATLAS detector operating at the Large Hadron Collider. No events are observed in any of the signal regions, and limits are set on model parameters within supersymmetric scenarios involving R-parity violation, split supersymmetry, and gauge mediation. In some of the search channels, the trigger and search strategy are based only on the decay products of individual long-lived particles, irrespective of the rest of the event. In these cases, the provided limits can easily be reinterpreted in different scenarios.

  • Publication . Article . Other literature type . 2020
    Open Access English
    Authors: 
    Konark Malhotra; Nitin Goyal; Aristeidis H. Katsanos; Angeliki Filippatou; Eva Mistry; Pooja Khatri; Mohammad Anadani; Alejandro M Spiotta; Else Charlotte Sandset; Amrou Sarraj; +9 more

    Limited data exist evaluating the effect of blood pressure (BP) on clinical outcomes among patients with acute ischemic stroke with large vessel occlusion treated with mechanical thrombectomy (MT). We sought to evaluate the association of BP levels on clinical outcomes among patients with acute ischemic stroke with large vessel occlusion treated with MT. Studies were identified that reported the association of systolic BP (SBP) or diastolic BP levels before, during, or after MT on the outcomes of patients with acute ischemic stroke treated with MT. Unadjusted and adjusted analyses of studies reporting odds ratios (OR adj ) per 10 mm Hg BP increment were performed. Our analysis included 25 studies comprising 6474 patients. Higher pre-MT mean SBP ( P =0.008) and post-MT maximum SBP ( P =0.009) levels were observed in patients who died within 3 months. Patients with 3-month functional independence were noted to have lower pre-MT ( P <0.001) and post-MT maximum SBP levels ( P <0.001). In adjusted analyses, increasing post-MT maximum SBP and diastolic BP levels were associated with 3-month mortality (OR adj , 1.19 [95% CI,1.00–1.43]; I 2 =78%, P value for Cochran Q test: 0.001) and symptomatic intracranial hemorrhage (OR adj , 1.65 [95% CI, 1.11–2.44]; I 2 =0%, P value for Cochran Q test: 0.80), respectively. Increasing pre- and post-MT mean SBP levels were associated with lower odds of 3-month functional independence (OR adj , 0.86 [95% CI, 0.77–0.96]; I 2 =18%, P value for Cochran Q test: 0.30) and (OR adj , 0.80 [95% CI, 0.72–0.89]; I 2 =0%, P value for Cochran Q test: 0.51), respectively. In conclusion, elevated BP levels before and after MT are associated with adverse outcomes among patients with acute ischemic stroke with large vessel occlusion.

  • Publication . Article . Preprint . Other literature type . 2013
    Open Access
    Authors: 
    Cornelius A. Rietveld; Sarah E. Medland; Jaime Derringer; Jian Yang; Tõnu Esko; Nicolas W. Martin; Harm-Jan Westra; Konstantin Shakhbazov; Abdel Abdellaoui; Arpana Agrawal; +173 more
    Countries: United Kingdom, Croatia, Netherlands, Australia, United States
    Project: NIH | NBER Center for Aging and... (5P30AG012810-15), EC | DEVHEALTH (269874), NSF | EAGER Proposal: Workshop ... (1064089), WT , NIH | FINANCIAL STATUS--RETIREM... (2P01AG005842-04), NIH | ECONOMICS OF AGING TRAINI... (5T32AG000186-10), EC | GMI (230374)

    A genome-wide association study (GWAS) of educational attainment was conducted in a discovery sample of 101,069 individuals and a replication sample of 25,490. Three independent single-nucleotide polymorphisms (SNPs) are genome-wide significant (rs9320913, rs11584700, rs4851266), and all three replicate. Estimated effects sizes are small (coefficient of determination R2 ≈ 0.02%), approximately 1 month of schooling per allele. A linear polygenic score from all measured SNPs accounts for ≈2% of the variance in both educational attainment and cognitive function. Genes in the region of the loci have previously been associated with health, cognitive, and central nervous system phenotypes, and bioinformatics analyses suggest the involvement of the anterior caudate nucleus. These findings provide promising candidate SNPs for follow-up work, and our effect size estimates can anchor power analyses in social-science genetics. Economics

  • Open Access
    Authors: 
    Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Maximiliano Sioli; Nello Bruscino; Toshi Sumida; Andrei Snesarev; +834 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.

  • Open Access English
    Authors: 
    Fergus J. Couch; Kyriaki Michailidou; Gustavo Mendoza-Fandiño; Janna Lilyquist; Emily Hallberg; Simona Agata; Christine B. Ambrosone; Irene L. Andrulis; Hoda Anton-Culver; Volker Arndt; +194 more
    Publisher: Uppsala universitet, Institutionen för immunologi, genetik och patologi
    Countries: Norway, Spain, Finland, China (People's Republic of), United Kingdom, United States, United Kingdom, Denmark, Spain, United Kingdom ...
    Project: NWO | Secure and gentle grip of... (11477), WT , NIH | Discovery Expansion and R... (5U19CA148065-04), NIH | Follow-up of Ovarian Canc... (3U19CA148112-04S1), EC | COGS (223175), CIHR , NIH | A genome-wide association... (5R01CA128978-02), NIH | Elucidating Loci Involved... (5U19CA148537-02)

    Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ∼11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction. B.C.A.C. was funded through a European Community Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175; COGS); Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692); the National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), R01 grants (CA128978, CA176785, CA192393), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative); the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, the Breast Cancer Res. Foundation, and the Ovarian Cancer Research Fund. CIMBA genotyping was supported by National Institutes of Health grant (CA128978); the Department of Defence (W81XWH-10-1-0341); and the Breast Cancer Res. Foundation. CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. This is the final version of the article. It first appeared from Nature Publishing Group via http://dx.doi.org/10.1038/ncomms11375